Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice
The potent, dual BAFF/APRIL inhibitor povetacicept significantly improves clinical disease activity in EAMG, associated with reductions in pathogenic anti-AChR autoantibodies and superior to comparator therapeutic interventions based on WT TACI-Fc, CD20 depletion, or FcRn inhibition. Povetacicept may therefore confer beneficial clinical outcomes in the treatment of MG and other autoantibody-related neurological diseases.
Authors
- Alessandra Consonni (ORCID: https://orcid.org/0000-0002-6610-764X)
- Fulvio Baggi (ORCID: https://orcid.org/0000-0002-4618-0102)
- Katherine E. Lewis (ORCID: https://orcid.org/0000-0003-2329-784X)
- Renato Mantegazza (ORCID: https://orcid.org/0000-0002-9810-5737)
- Stacey R. Dillon (ORCID: https://orcid.org/0000-0001-8758-3795)
- Stanford L. Peng (ORCID: https://orcid.org/0000-0001-7445-2542)
- Martina Miglietti (ORCID: https://orcid.org/0000-0001-5685-1777)
- Elena Rinaldi (ORCID: https://orcid.org/0000-0003-0744-7238)
- NingXin Wang
- Elisa Puleo
Institutions
- Alpine Immune Sciences (United States) (US)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.3389/fimmu.2025.1533093
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Vertex Pharmaceuticals
- Ministero della Salute